Drug Patents owned by Merck
1. Drug name - EMEND
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MERCK | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(4 years from now) | |
Drugs and Companies using APREPITANT ingredient
Treatment: Prevention of postoperative nausea and vomiting; for the prevention of nausea and vomiting associated with chemotherapy
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 40MG | CAPSULE;ORAL | Discontinued |
| 80MG | CAPSULE;ORAL | Prescription |
| 125MG | CAPSULE;ORAL | Prescription |
2. Drug name - SINGULAIR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8007830 | MERCK | Granule formation |
Oct, 2022
(19 days from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 4MG BASE/PACKET | GRANULE;ORAL | Prescription |
3. Drug name - ZOLINZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7456219 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(4 years from now) | |
| CN1901895A | MERCK | Methods Of Treating Cancer With Hdac Inhibitors |
Aug, 2010
(12 years ago) | |
| CN102188415A | MERCK | Method Of Treating Cancer With Hdac Inhibitor |
Mar, 2013
(9 years ago) | |
| CN1870985B | MERCK | Method Of Hdac Inhibitor For Treating Cancer |
Oct, 2013
(8 years ago) | |
| CN1870985A | MERCK | Method For Treating Cancer With Hdac Inhibitor |
Oct, 2013
(8 years ago) | |
| CN101259120A | MERCK | Methods Of Inducing Terminal Differentiation |
Mar, 2023
(4 months from now) | |
| CN101259120B | MERCK | Suberoylanilide Hydroxamic Acid Or A Pharmaceutically Acceptable Salt Thereof In Preparing A Medicament For Inducing Terminal Differentiation |
Mar, 2023
(4 months from now) | |
| IN236771B | MERCK | A Pharmaceutical Composition For Oral Administration |
Mar, 2023
(4 months from now) | |
| IN200402721P1 | MERCK | A Pharmaceutical Composition For Oral Administration |
Mar, 2023
(4 months from now) | |
| EP1487426A4 | MERCK | Methods Of Inducing Terminal Differentiation |
Jan, 2019
(3 years ago) | |
| EP1487426A2 | MERCK | Methods Of Inducing Terminal Differentiation |
Jan, 2019
(3 years ago) | |
| EP1487426B1 | MERCK | Methods Of Inducing Terminal Differentiation |
Jan, 2019
(3 years ago) | |
| EP2082737B1 | MERCK | Methods Of Inducing Terminal Differentiation |
Mar, 2023
(4 months from now) | |
| EP2082737A2 | MERCK | Methods Of Inducing Terminal Differentiation |
Mar, 2023
(4 months from now) | |
| EP2082737A3 | MERCK | Methods Of Inducing Terminal Differentiation |
Mar, 2023
(4 months from now) | |
| EP1663194A4 | MERCK | Method Of Treating Cancer With Hdac Inhibitors |
Aug, 2024
(1 year, 10 months from now) | |
| EP1663194A2 | MERCK | Use Of Saha For Treating Mesothelioma |
Aug, 2024
(1 year, 10 months from now) | |
| EP1663194B1 | MERCK | Use Of Saha For Treating Mesothelioma |
Aug, 2024
(1 year, 10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7652069 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(4 months from now) | |
| US8067472 | MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(4 months from now) | |
| US8101663 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(4 months from now) | |
| US7732490 | MERCK | Methods of treating cancer |
Mar, 2023
(4 months from now) | |
| US7851509 | MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(1 year, 4 months from now) | |
| US7399787 | MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(2 years from now) | |
| US8093295 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(3 years from now) | |
| US8450372 | MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(5 years from now) | |
Drugs and Companies using VORINOSTAT ingredient
Treatment: Treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.